Shots:

• The approval is based on ENSEMBLE PLUS study- which demonstrated similar frequency and severity of IRRs for 2hrs. Ocrevus infusion time vs conventional 3.5hrs in patients with RRMS. The initial dose is given as two 300mg infusions given 2wks. apart and a subsequent dose of single 600mg infusions were administered over a shorter- 2hrs. time
• Results: frequency of IRRs post 600mg infusion (24.6% vs 23.1%)- majority of IRRs were mild or moderate- and >98% resolved in both groups without complication
• Ocrevus is a humanized mAb designed to target CD20-positive B cells and is the first and only therapy approved for both RMS and PPMS

­ Ref: Genentech | Image: Xconomy